A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

Abstract Background Anlotinib, a tyrosine kinase inhibitor, has shown encouraging anti-tumor activity in esophageal squamous cell carcinoma (ESCC). This study was designed to assess the efficacy and safety of anlotinib plus paclitaxel and cisplatin (TP) as first-line therapy for advanced ESCC. Metho...

Full description

Bibliographic Details
Main Authors: Ning Li, Tao Wu, Yong-Gui Hong, Yan-Zhen Guo, Yu-Feng Cheng, Yi-Jie Ma, Liang-Yu Bie, Dong-Hai Cui, Xiao-Hui Gao, Bing-Xu Tan, Bao-Sheng Li, Su-Xia Luo, Jun-Sheng Wang
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Medicine
Subjects:
Anlotinib
Paclitaxel
Cisplatin
Advanced esophageal squamous cell carcinoma
Efficacy
Safety
Online Access:https://doi.org/10.1186/s12916-022-02649-x

Internet

https://doi.org/10.1186/s12916-022-02649-x

Similar Items